Tetraphase

TTPH NASDAQ
0.6551
-0.0254
-3.73%
Closed 16:25 06/17 EDT
Open
0.6900
Prev Close
0.6805
High
0.7000
Low
0.6400
Volume
595.87K
Avg Vol (3M)
544.55K
52 Week High
4.350
52 Week Low
0.6400
% Turnover
1.10%
Market Cap
35.55M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Tetraphase TTPH stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Tetraphase Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections. The Company also develops TP-6076 for multidrug-resistant gram-negative infections. Eravacycline is a fluorocycline antibiotic. The Company is conducting a global Phase III clinical program for eravacycline called Investigating Gram-Negative Infections Treated with Eravacycline (IGNITE). TP-271 is a fully synthetic fluorocycline being developed for respiratory disease caused by bacterial biothreat pathogens in healthy volunteers.
MORE >

Recently

Name
Price
%Change